Skip to main content
Chronic Graft-versus-host-diseaseDrugPhase 3

What this study is

This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).

What's being tested

  • INCA034176

    Intervention · DRUG

  • Placebo

    Intervention · DRUG

  • Corticosteroids

    Intervention · DRUG

    Oral/IV Infusion

Both INCA034176 and Placebo

IV infusion

Study details

Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357)
Sponsor
Incyte Corporation
Conditions
Chronic Graft-versus-host-disease
Enrolling
240 people
Starts
2025-01-21
Est. completion
2030-03-31
Design
Quadruple-blind, randomized, parallel groups, Phase 3
Record
View on ClinicalTrials.gov ↗